Drug Profile


Alternative Names: RS 25560 197

Latest Information Update: 28 Nov 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Roche Palo Alto LLC
  • Class Antiparkinsonians; Anxiolytics; Drug withdrawal therapies; Imidazoles; Neuropsychotherapeutics; Small molecules; Thiones
  • Mechanism of Action Dopamine beta hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure; Hypertension

Most Recent Events

  • 20 Jan 1999 A preclinical study has been added to the Heart Failure pharmacodynamics section
  • 02 Apr 1998 A study has been added to the Heart Failure adverse events section
  • 02 Apr 1998 Two studies have been added to the Heart Failure pharmacodynamics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top